Stamford-based Purdue Pharma L.P. and San Diego-based AnaBios Corp. announced a collaboration this week to advance the research of non-opioid compounds to treat chronic pain.
The goal of the collaboration is to accelerate Purdue’s Nav1.7 sodium ion channel drug candidates utilizing AnaBios’ Phase-X discovery platform to develop treatments for chronic pain, according to a news release.
The two companies will form a joint steering committee to manage preclinical and clinical development of the lead molecule. The companies will own any intellectual property developed jointly.
“Through this unique collaboration we have a tremendous opportunity to quickly advance new treatments into the clinic and potentially serve the many chronic pain patients that cannot find relief with existing medications,” Don Kyle, vice president, discovery research at Purdue, said in the release. “Our ability to select clinical candidates based on experiments performed in native human tissues will provide the greatest chance of success.”
